Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center

CompletedOBSERVATIONAL
Enrollment

170

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
QT Interval Prolongation
Interventions
DEVICE

AliveCor handheld mobile ECG

"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."

Trial Locations (1)

46202

Eskenazi Health, Indianapolis

All Listed Sponsors
collaborator

Purdue University

OTHER

lead

Indiana University

OTHER

NCT02898337 - Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center | Biotech Hunter | Biotech Hunter